EUVIMEDEUVIMED entdecken
Crossref

Evaluating the Heterogeneity of Advanced Prostate Cancer by 18 F‐DCFPyL and 18 F‐FDG PET/CT in a Prospective Cohort

GuangHao Chen iD, YueKai Li iD, ShangZhen Geng iD, LinChen Lv iD, Yong Wang iD, Xin Li iD, ShouZhen Chen iD, BenKang Shi iD

The Prostate · 2025

DOI: 10.1002/pros.24881 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Prostate, 2025. Verfasst von GuangHao Chen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Qilu Hospital of Shandong University, Jinan, China. Hauptthemen laut MEDLINE: Fluorodeoxyglucose F18, Positron Emission Tomography Computed Tomography, Prostatic Neoplasms, Urea. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: This work was supported by the National Natural Science Foundation of China (Grant Nos. 82170790 and 81970661) to BenKang Shi, the National Natural Science Fou….

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

18 F‐DCFPyL (targeted PSMA) and 18 F‐FDG dual‐tracer PET/CT combination with next‐generation sequencing was applied in a prospective cohort of men with prostate cancer to identify the clinical and genetic characteristics with heterogeneous PET/CT imaging features.

Methods

104 men with documented prostate cancer underwent 18 F‐DCFPyL and 18 F‐FDG PET/CT, of which 83 underwent next‐generation sequencing for detecting variation of AR , TP53, RB1, PTEN , etc. Lesions were classified into DCFPyL+FDG± lesions and DCFPyL‐FDG+ lesions and analyzed for heterogeneous distribution. We divided the patients with positive lesions into DCFPyL+FDG± group and DCFPyL‐FDG+ group, then compared the differences in clinical features and genetic mutations between the two groups with CRPC.

Results

Overall, 92 men had positive lesions detected. By comparing lesion distribution with the DCFPyL+FDG ± , DCFPyL‐FDG+ disease had higher proportions of visceral metastases (4.1% vs. 1.0%, p = 0.002). DCFPyL‐FDG+ was more frequently found in CRPC cohorts, and in the CRPC cohort, patients with DCFPyL‐FDG+ lesions often had worse PSA response. Exploratory analysis showed that TP53 and/or RB1 mutations might be a risk factor for DCFPyL‐FDG+ disease (OR = 10.625, 95% CI 3.492–32.332, p < 0.001).

Conclusion

Patients with DCFPyL‐FDG+ lesions were more likely to have visceral metastases detected, be found in castration‐resistant cohorts, have TP53 and/or RB1 mutations detected, and have poor therapeutic response compared to patients with DCFPyL+FDG± lesions. Therefore, dual‐tracer ( 18 F‐DCFPyL and 18 F‐FDG) PET/CT is recommended for patients with low PSMA expression incompatible with the true burden of the disease and those with TP53 and/or RB1 mutations to better evaluate the disease burden, tumor heterogeneity, and prognosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fluorodeoxyglucose F18Positron Emission Tomography Computed TomographyProstatic NeoplasmsUreaLysineHumansMaleProspective StudiesAgedMiddle AgedRadiopharmaceuticalsRetinoblastoma Binding ProteinsTumor Suppressor Protein p53Ubiquitin-Protein LigasesAged, 80 and overCohort StudiesHigh-Throughput Nucleotide Sequencing

Stichwörter der Autor:innen

FDGPSMARB1TP53prostate cancer

Substanzen

Fluorodeoxyglucose F182-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acidUreaLysineRadiopharmaceuticalsRetinoblastoma Binding ProteinsRB1 protein, humanTumor Suppressor Protein p53Ubiquitin-Protein LigasesTP53 protein, human

Autor:innen und Institutionen

  • Department of Urology, Qilu Hospital of Shandong University, Jinan, China.
  • Department of Nuclear Medicine, Qilu Hospital of Shandong University, Jinan, China.

ORCID-Profile: GuangHao Chen, YueKai Li, ShangZhen Geng, LinChen Lv, Yong Wang, Xin Li, ShouZhen Chen, BenKang Shi

Förderung

  • This work was supported by the National Natural Science Foundation of China (Grant Nos. 82170790 and 81970661) to BenKang Shi, the National Natural Science Fou…

Zitieren

APA

Chen, G., Li, Y., Geng, S., Lv, L., Wang, Y., Li, X., Chen, S., & Shi, B. (2025). Evaluating the Heterogeneity of Advanced Prostate Cancer by 18 F‐DCFPyL and 18 F‐FDG PET/CT in a Prospective Cohort. The Prostate. https://doi.org/10.1002/pros.24881

Vancouver

Chen G, Li Y, Geng S, Lv L, Wang Y, Li X, et al. Evaluating the Heterogeneity of Advanced Prostate Cancer by 18 F‐DCFPyL and 18 F‐FDG PET/CT in a Prospective Cohort. The Prostate. 2025. doi:10.1002/pros.24881

BibTeX
@article{Chen2025,
  author = {Chen, GuangHao and Li, YueKai and Geng, ShangZhen and Lv, LinChen and Wang, Yong and Li, Xin and Chen, ShouZhen and Shi, BenKang},
  title = {Evaluating the Heterogeneity of Advanced Prostate Cancer by 18 F‐DCFPyL and 18 F‐FDG PET/CT in a Prospective Cohort},
  journal = {The Prostate},
  year = {2025},
  doi = {10.1002/pros.24881}
}
Kostenlos starten →